Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 10, 2023

Lazertinib vs Gefitinib Tyrosine Kinase Inhibitors for Treatment-Naïve EGFR-Mutated Advanced NSCLC

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
J Thorac Oncol 2023 Oct 01;18(10)1351-1361, T Reungwetwattana, BC Cho, KH Lee, YK Pang, CH Fong, JH Kang, YG Lee, CS Lim, P Danchaivijitr, YN Lim, Y Lee, SH How, S Geater, SS Lee, YJ Min, JH Kim, JS Lee, GW Lee, RA Soo, SY Lee, S Choi, MJ Ahn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading